Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

Overcoming immune resistance in HR-MDS: Detailed safety and efficacy Phase II data on bexmarilimab to be presented at EHA 2025

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, today announced that data from its ongoing BEXMAB study evaluating bexmarilimab in patients with high-risk myelodysplastic syndromes (HR-MDS) have been accepted for an oral presentation at the 30th European Hematology Association’s (EHA 2025) Congress, taking place in Milan from June 12–15, 2025.

The oral presentation will feature detailed efficacy and safety results from the study of bexmarilimab in combination with standard-of-care (azacitidine) in frontline with HR-MDS and those with refractory or relapsed HR-MDS who have failed hypomethylating agent (HMA) therapies (r/r MDS). This follows the recent positive findings of the Phase II data from the BEXMAB study, and reaffirms bexmarilimab’s mechanism of action and its potential in improving outcomes for patients with MDS.

• Juho Jalkanen, CEO of Faron Pharmaceuticals, said: “We are thrilled to see bexmarilimab’s data receive acceptance for oral presentation at EHA, following similar recognition at MDS and ASCO. This continued momentum reinforces our belief that bexmarilimab holds real promise as a much-needed therapeutic option for patients with higher-risk MDS, a rare and challenging condition with few effective treatments. We remain deeply committed to advancing its development and bringing meaningful innovation to those who need it most.”

The details of the oral presentation are as follows:

Session: Oral presentation

Presenter: Dr. Mika Kontro, MD, PhD

Date and Time: 15 June 2025 11:00 – 12:15 CEST

Location: Milan, Italy

Abstract no: S178

Further details will be shared closer to the conference dates.

About bexmarilimab